Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Incyte Appoints Eiji Ueda as Japan Chief
March 27, 2024
- SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
- One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
- Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
- CureApp Files Alcoholism Therapy App in Japan
March 26, 2024
- Eisai Settles Lenvima Patent Suit with Sun Pharma
March 26, 2024
- EMA Panel Gives Go-Ahead for Xtandi Use in Earlier Setting: Astellas
March 26, 2024
- Boehringer’s Brigimadlin Earns Sakigake Designation
March 26, 2024
- Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
- Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
- Lilly, Nippon Shinyaku Pair Up on Blood Cancer Med in Japan
March 26, 2024
- Daiichi Sankyo Eyes 7 Additional Indications for Enhertu by 2026
March 25, 2024
- Ono Hooks Up with Oxford on Drug Discovery Research
March 25, 2024
- EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
- Iclusig Gets Additional FDA Nod for Iclusig in Ph+ ALL: Takeda
March 25, 2024
- Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk
March 25, 2024
- Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
- Japan, US CROs to Collaborate to Address Drug Lags/Losses
March 22, 2024
- Astellas Gives 1.5% Pay Raise to Acquire Best Talents
March 22, 2024
- FDA Clears Orchard’s Lenmeldy Gene Therapy for MLD
March 22, 2024
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…